SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Disc Medicine, Inc. (IRON) has a negative trailing P/E of -11.0, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 48.0 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -9.10%, forward earnings yield 2.08%.
Criteria proven by this page:
- VALUE (93/100, Pass) — analyst target implies upside (+56.4%).
- Forward P/E 48.0 — analysts expect a return to profitability with estimated EPS of $1.47 for FY2030.
- Trailing Earnings Yield -9.10% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 2.08% as earnings recover.
- Analyst consensus target $110.25 (+56.4% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 51/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
93/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — IRON
Valuation Multiples
P/E (TTM)-11.0
Forward P/E48.0
PEG RatioN/A
Forward PEGN/A
P/B Ratio3.15
P/S Ratio0.00
EV/EBITDA-11.7
Per Share Data
EPS (TTM)$-6.01
Forward EPS (Est.)$1.47
Book Value / Share$20.96
Revenue / Share$0.00
FCF / Share$-5.14
Yields & Fair Value
Earnings Yield-9.10%
Forward Earnings Yield2.08%
Dividend Yield0.00%
Analyst Target$110.25 (+56.4%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2020 |
-4.1 |
0.00 |
-7.61 |
0.00 |
- |
| 2021 |
-0.6 |
-0.01 |
-0.36 |
0.00 |
- |
| 2022 |
-0.4 |
-1.17 |
0.12 |
0.00 |
- |
| 2023 |
-16.9 |
0.18 |
3.73 |
0.00 |
- |
| 2024 |
-16.0 |
-1.01 |
3.95 |
0.00 |
- |
| 2025 |
-13.2 |
-0.26 |
3.79 |
0.00 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2020 |
$-31.53 |
$0.00 |
$-47.66M |
- |
| 2021 |
$-9.49 |
$0.00 |
$-41.01M |
- |
| 2022 |
$-3.96 |
$0.00 |
$-46.09M |
- |
| 2023 |
$-3.42 |
$0.00 |
$-76.43M |
- |
| 2024 |
$-3.96 |
$0.00 |
$-109.36M |
- |
| 2025 |
$-6.01 |
$0.00 |
$-212.18M |
- |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$-6.89 |
$-8.09 – $-5.46 |
$3.16M |
$1.92M – $6.35M |
9 |
| 2027 |
$-7.03 |
$-9.10 – $-5.34 |
$27.07M |
$2.36M – $104.83M |
9 |
| 2028 |
$-5.47 |
$-7.76 – $-2.57 |
$136.05M |
$136.05M – $136.05M |
10 |
| 2029 |
$-2.92 |
$-6.74 – $-1.43 |
$353.06M |
$214.9M – $709.46M |
4 |
| 2030 |
$1.47 |
$0.72 – $3.40 |
$557.37M |
$339.26M – $1.12B |
4 |
